Serum Glucose and Cancer Risk: A Meta-Analysis

Serum Glucose and Cancer Risk: A Meta-Analysis

Metabolic health, particularly blood glucose regulation, has been increasingly linked to cancer risk. Crawley and colleagues conducted a meta-analysis to evaluate the association between serum glucose levels and the risk of developing cancer across multiple populations and study designs.
This analysis pooled data from numerous prospective cohort studies examining fasting blood glucose levels and subsequent cancer incidence. Participants were grouped based on glucose levels, including normal, impaired, and elevated ranges, and outcomes included the development of various cancers such as colorectal, breast, and pancreatic cancer. The large sample size allowed for more robust estimates of risk across different populations.
The findings demonstrated that higher serum glucose levels were associated with an increased risk of developing cancer, even within ranges not classified as overt diabetes. The association appeared dose-dependent, with progressively higher glucose levels correlating with greater cancer risk. This relationship is thought to be mediated through mechanisms such as insulin resistance, chronic inflammation, and increased availability of glucose to fuel tumor growth.
While observational in nature and unable to establish causation, this meta-analysis highlights the importance of metabolic health in cancer prevention. Maintaining healthy blood glucose levels through diet, physical activity, and overall lifestyle may play a role in reducing cancer risk, supporting a broader integrative approach to long-term health.

Reference:

Crawley DJ, Holmberg L, Melvin JC, Loda M, Chowdhury S, Rudman SM, Van Hemelrijck M. Serum glucose and risk of cancer: a meta-analysis. BMC Cancer. 2014;14:985. doi:10.1186/1471-2407-14-985. PMID: 25526881; PMCID: PMC4320469.